1

Relatlimab: A Detailed Examination into BMS-986016 and its Prospects

bms-986016715496
Relatlimab, formerly known as BMS-986016, represents a groundbreaking medicinal approach in cancer treatment, functioning as a selective LAG-3 antagonist. Its working principle centers around neutralizing the LAG-3 https://www.targetmol.com/compound/relatlimab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story